Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 589492107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
EcoR1 Capital, LLC
13G/A
Amendment 2
|
0.6% |
8/14/2026
Event 6/30/2026
|
|
| EcoR1 Capital, LLC | 0.6% | ||
| Oleg Nodelman | 0.6% | ||
| EcoR1 Capital Fund Qualified, L.P. | 0.6% | ||
|
EcoR1 Capital, LLC
13G/A
Amendment 1
|
8.4% |
5/15/2026
Event 3/31/2026
|
|
| EcoR1 Capital, LLC | 8.4% | ||
| Oleg Nodelman | 8.4% | ||
| EcoR1 Capital Fund Qualified, L.P. | 7.8% | ||
|
Northpond Ventures, LP
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Northpond Ventures, LP | 0% | ||
| Northpond Ventures GP, LLC | 0% | ||
| Northpond Ventures II, LP | 0% | ||
| Northpond Ventures II GP, LLC | 0% | ||
| NPV Listed, LLC | 0% | ||
| Northpond Ventures, LLC | 0% | ||
| Michael P. Rubin | 0% | ||
| Janus Henderson Group PLC 13G/A Amendment 7 | 0% |
2/17/2026
Event 12/31/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
0% |
2/13/2026
Event 12/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 0% | ||
| FHMLSP, L.P. | 0% | ||
| FHMLSP, L.L.C. | 0% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
|
EcoR1 Capital, LLC
13G
|
9.4% |
1/9/2026
Event 1/2/2026
|
|
| EcoR1 Capital, LLC | 9.4% | ||
| Oleg Nodelman | 9.4% | ||
| EcoR1 Capital Fund Qualified, L.P. | 8.8% | ||
|
683 Capital Management, LLC
13G
|
8.2% |
1/6/2026
Event 12/29/2025
|
|
| 683 Capital Management, LLC | 8.2% | ||
| 683 Capital Partners, LP | 8.2% | ||
| Ari Zweiman | 8.2% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 6
|
10.2% |
11/14/2025
Event 9/30/2025
|
|
| Janus Henderson Group PLC | 10.2% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 8.7% | ||
|
Mangrove Partners IM, LLC
13G/A
Amendment 1
|
4.9% |
11/14/2025
Event 9/30/2025
|
|
| Mangrove Partners IM, LLC | 4.9% | ||
| Nathaniel August | 4.9% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
4.1% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.1% | ||
| FHMLSP, L.P. | 4.1% | ||
| FHMLSP, L.L.C. | 4.1% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.1% | ||
| FHMLSP Overage, L.P. | 1.1% | ||
| FHMLSP Overage, L.L.C. | 1.1% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.5% | ||
| FHMLS XI, L.P. | 0.5% | ||
| FHMLS XI, L.L.C. | 0.5% | ||
| James N. Topper | 0.2% | ||
| Patrick J. Heron | 0.2% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 5
|
11.1% |
8/14/2025
Event 6/30/2025
|
|
| Janus Henderson Group PLC | 11.1% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.6% | ||
|
Northpond Ventures, LP
13G
|
6.9% |
6/11/2025
Event 6/4/2025
|
|
| Northpond Ventures, LP | 4.4% | ||
| Northpond Ventures GP, LLC | 4.4% | ||
| Northpond Ventures II, LP | 2.1% | ||
| Northpond Ventures II GP, LLC | 2.1% | ||
| NPV Listed, LLC | 0.4% | ||
| Northpond Ventures, LLC | 0.4% | ||
| Michael P. Rubin | 6.9% | ||
|
Rock Springs Capital Management LP
13G/A
Amendment 5
|
4.2% |
5/15/2025
Event 3/31/2025
|
|
| Rock Springs Capital Management LP | 4.2% | ||
| Rock Springs Capital LLC | 4.2% | ||
| Rock Springs Capital Master Fund LP | 3.2% | ||
| Mark Bussard | 4.2% | ||
| Kris Jenner | 4.2% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 4
|
14.3% |
5/14/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC | 14.3% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 12.7% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 4
|
14.3% |
5/14/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC | 14.3% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 12.7% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 2
|
1.1% |
5/12/2025
Event 3/31/2025
|
|
| Adage Capital Management, L.P. | 1.1% | ||
| Robert Atchinson | 1.1% | ||
| Phillip Gross | 1.1% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
5.1% |
4/4/2025
Event 4/1/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 3.5% | ||
| FHMLSP, L.P. | 3.5% | ||
| FHMLSP, L.L.C. | 3.5% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.9% | ||
| FHMLSP Overage, L.P. | 0.9% | ||
| FHMLSP Overage, L.L.C. | 0.9% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.5% | ||
| FHMLS XI, L.P. | 0.5% | ||
| FHMLS XI, L.L.C. | 0.5% | ||
| James N. Topper | 5.1% | ||
| Patrick J. Heron | 5.1% | ||
| Albert Cha | 4.4% | ||
| James Brush | 4.4% | ||
| Daniel Estes | 0.5% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 3
|
11.0% |
2/14/2025
Event 12/31/2024
|
|
| Janus Henderson Group PLC | 11.0% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 10.1% | ||
|
Adage Capital Partners GP, L.L.C.
13G/A
Amendment 1
|
5.6% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 5.6% | ||
| Adage Capital Partners GP, L.L.C. | 0% | ||
| Robert Atchinson | 5.6% | ||
| Phillip Gross | 5.6% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 2
|
10.3% |
12/6/2024
Event 11/29/2024
|
|
| Janus Henderson Group PLC | 10.3% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 9.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 1.99 k | $800.00 |
| 2026 Q2 | 65 | 56.6 M | $18.0 M |
| 2026 Q1 | 69 | 75.4 M | $24.9 M |
| 2025 Q4 | 80 | 62.0 M | $25.8 M |
| 2025 Q3 | 95 | 100 M | $205 M |
| 2025 Q2 | 101 | 98.7 M | $268 M |
| 2025 Q1 | 102 | 111 M | $250 M |
| 2024 Q4 | 99 | 115 M | $403 M |
| 2024 Q3 | 85 | 106 M | $435 M |
| 2024 Q2 | 86 | 101 M | $363 M |
| 2024 Q1 | 90 | 86.8 M | $287 M |
| 2023 Q4 | 73 | 80.7 M | $186 M |
| 2023 Q3 | 60 | 70.5 M | $90.4 M |
| 2023 Q2 | 58 | 64.7 M | $84.5 M |
| 2023 Q1 | 62 | 61.1 M | $43.2 M |
| 2022 Q4 | 64 | 61.6 M | $46.2 M |
| 2022 Q3 | 68 | 68.0 M | $58.5 M |
| 2022 Q2 | 72 | 74.2 M | $82.7 M |
| 2022 Q1 | 64 | 89.8 M | $99.9 M |
| 2021 Q4 | 80 | 92.1 M | $146 M |
| 2021 Q3 | 68 | 88.4 M | $212 M |
| 2021 Q2 | 80 | 92.3 M | $290 M |
| 2021 Q1 | 76 | 97.4 M | $325 M |
| 2020 Q4 | 50 | 59.9 M | $211 M |
| 2020 Q3 | 29 | 15.5 M | $38.1 M |
| 2020 Q2 | 25 | 7.28 M | $22.3 M |
| 2020 Q1 | 15 | 3.28 M | $3.42 M |
| 2019 Q4 | 15 | 1.24 M | $4.08 M |
| 2019 Q3 | 17 | 1.78 M | $5.21 M |
| 2019 Q2 | 19 | 1.80 M | $4.39 M |